Foggy visual field defect: Comments

Survey of Ophthalmology

Volumn 48, Issue 4, 2003, Pages 447-451

  Foroozan, Rod ^a   Buono, Lawrence M ^a   Vaphiades, Michael S ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Arteriovenous malformation (AVM); Homonymous hemianopia; Migraine; Topiramate; Visual field loss

Indexed keywords

TOPIRAMATE;

ADULT; ARTERIOVENOUS MALFORMATION; ATAXIA; CASE REPORT; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CRANIOTOMY; DEMYELINATION; DIPLOPIA; DROWSINESS; EFFUSION; ELECTROENCEPHALOGRAM; FEMALE; HOMONYMOUS HEMIANOPIA; HUMAN; INFARCTION; LATERAL GENICULATE BODY; MOOD DISORDER; MYOPIA; NERVE LESION; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OPTIC TRACT; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; REVIEW; SEIZURE; TUMOR; UVEA DISEASE; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL SYSTEM;

EID: 0037677193     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(03)00051-1     Document Type: Article

References (14)

1. Biton V., Montouris G.D., Ritter F., et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology. 52:1999;1330-1337.
2. Dodgson S.J., Shank R.P., Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isozymes. Epilepsia. 41:2000;S35-S39.
3. Gilliam F., Wyllie E. Ictal amaurosis: MRI, EEG, and clinical features. Neurology. 45:1995;1619-1621.
4. Miller N.R., Newman N.J. Topical diagnosis of lesions in the visual sensory pathway. Miller N.R., Newman N.J. ed 5 Walsh & Hoyt's Clinical Neuro-ophthaomology. Vol 1:1998;237-386 Williams & Wilkins.
5. Ponjavic V., Andreasson S. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol. 102:2001;63-72.
6. Rhee D.J., Goldberg M.J., Parrish R.K. Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol. 119:2001;1721-1723.
7. Sachdeo R.C., Glauser T.A., Ritter F., et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 52:1999;1882-1887.
8. Sankar P.S., Pasquale L.R., Grosskreutz C.L. Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch Ophthalmol. 119:2001;1210-1211.
9. Sen H.A., O'Halloran H.S., Lee W.B. Case reports and small case series: topiramate-induced acute myopia and retinal striae. Arch Ophthalmol. 119:2001;775-777.
10. Sharief M., Viteri C., Ben-Menachem E., et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res. 25:1996;217-224.
11. Storey J.R., Calder C.S., Hart D.E., Potter D.L. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 41:(Suppl 1):2001;S3-S11.
12. Thompson P.J., Baxendale S.A., Duncan J.S., Sander J.W. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 69:2000;636-641.
13. White H.S., Brown S.D., Woodhead J.H., et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 28:1997;167-179.
14. Wilton L.V., Stephens M.D., Mann R.D. Visual field defect associated with vigabatrin: observational cohort study. BMJ. 319:1999;1165-1166.